Developer docs
API playgroundTry for free, no card

Search company profiles

Polyamyna

Full company profile

uuid0003xdl

Namestring
Polyamyna
Legal namestring
Polyamyna Nanotech Inc.
Websiteurl
polyamyna.ca
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Polyamyna Nanotech Inc. is a Canadian biotechnology company (founded 2017–2019, headquartered in St. John's, Newfoundland and Labrador) that develops nanotechnology-based antimicrobial solutions targeting drug-resistant pathogens and healthcare-associated infections (HAIs). It operates a portfolio of three core technologies: Keep Klear™, a continuously active transparent microbicidal coating with a 7-day residual antimicrobial effect and a proprietary electrostatic molecular-arm mechanism; MicroDome®, a registered-trademark antimicrobial additive engineered for integration into polymer matrices (PLA, nylon, polypropylene, thermoplastics, and 3D printing); and PRP-2019, an adjuvant antibiotic platform designed to restore efficacy of existing antibiotics against multi-drug-resistant bacteria without directly killing them. Supporting modules in earlier stages include antimicrobial fabrics, antifouling marine coatings, anti-MIC coatings for defense/aerospace, and a point-of-care diagnostic device for AMR pathogens. An R&D subsidiary was established in Chennai, India in 2021 at Ticel Biopark II.

The company's revenue model is structured around product sales of Keep Klear coatings to healthcare facilities, plus licensing/royalty arrangements for MicroDome (sold or licensed to polymer manufacturers) and potentially PRP-2019 (to pharmaceutical partners). Target verticals span hospitals and long-term care facilities, medical device manufacturers, polymer/OEM manufacturers, defense and aerospace, and marine/offshore infrastructure. GTM combines direct enterprise field sales into healthcare accounts with OEM/embedded integration partnerships for its polymer additive.

Polyamyna remains primarily pre-commercial. Its main activity to date is clinical validation: integration trials with Newfoundland & Labrador Health Services (NLHS) and a human factors study with W21C in Calgary, alongside the Health Canada PMRA approval process for Keep Klear targeted for Q4 2025. Total disclosed funding is approximately $2.26M USD-equivalent across a Genesis pre-seed, 2019 government grants (NL Government, NRC IRAP), 2020 SDTC funding, a 2023 NL Department of Industry non-dilutive grant, and a 2023 SEC Form D debt-to-equity conversion. No institutional VC/PE participation is disclosed.

Short descriptiontext

Polyamyna Nanotech is a Canadian biotechnology company developing nanotechnology-based antimicrobial coatings (Keep Klear™), polymer-integrated antimicrobial additives (MicroDome®), and antibiotic adjuvant therapeutics (PRP-2019) to combat drug-resistant pathogens and healthcare-associated infections for hospitals, OEMs, defense, and marine markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSt. John's, Canada
HQ citystring
St. John's
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial coatings, antimicrobial additives, antibiotic adjuvants, infection prevention, drug resistance therapeutics
Industry3 codes
PRIMARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing3252
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Miscellaneous Chemical Products2890
  • Miscellaneous Plastics Products3080
Product category
Antimicrobial Coatings & Infection Prevention Technologies
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Keep Klear Microbicidal Coatings
TypeHardware Sales
Description

Sale of continuously active antimicrobial coating products for healthcare facility surfaces. Revenue derived from product sales to hospitals and healthcare systems with demonstrated residual activity lasting up to 7 days per application.

polyamyna.ca
2MicroDome Antimicrobial Additive
TypeLicensing Royalties
Description

Licensing and sale of antimicrobial additive technology to polymer manufacturers for integration into their products. Targets healthcare, aerospace, defense, and consumer goods manufacturers.

polyamyna.ca
3PRP-2019 Adjuvant Therapeutics
TypeLicensing Royalties
Description

Antibiotic adjuvant compounds for co-administration with existing antibiotics to combat drug-resistant bacteria. Potential licensing to pharmaceutical companies or development as standalone therapeutic products.

polyamyna.ca
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Keep Klear™
Description

Continuously active transparent microbicidal coating technology offering a 7-day residual effect for infection control in healthcare settings.

polyamyna.ca
+2 more records
Core offering1 text field

Polyamyna develops and sells nanotechnology-based antimicrobial products that combat multi-drug-resistant pathogens and healthcare-associated infections. Its core offerings include Keep Klear™, a continuously active transparent microbicidal coating with a 7-day residual effect for healthcare facility surfaces; MicroDome®, an antimicrobial additive for integration into polymer matrices used in manufacturing; and PRP-2019, an antibiotic adjuvant platform that restores efficacy of existing antibiotics against drug-resistant bacteria. Customers include hospitals, healthcare systems, polymer manufacturers, and defense/aerospace integrators.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Eliminates >99% of MRSA within 15 minutes of contact on coated surfaces
+6 more records
Product overview1 text field

Polyamyna Nanotech Inc. is a biotechnology company offering a portfolio of antimicrobial technologies. The core offerings include Keep Klear™ (a continuously active microbicidal coating with 7-day residual effect), MicroDome® (an antimicrobial additive for polymer integration), and PRP-2019 (an adjuvant antibiotic technology platform). Additional modules include antimicrobial fabrics, antifouling technologies for marine applications, Anti-MIC technologies for defense and aerospace, and a point-of-care diagnostic device for AMR pathogens (in development). These products work together to address infection prevention across healthcare, industrial, and defense settings.

Product and service6 records
1Keep Klear™
CategoryAntimicrobial Microbicidal Coating
Description

Continuously active transparent microbicidal coating technology offering a 7-day residual antimicrobial effect for healthcare surfaces. It eliminates up to 99.99% of infection-causing bacteria, viruses, fungi, and Human Coronavirus, and over 97% of spores and 99.9% of biofilms on coated surfaces; dries in under 10 minutes, withstands rigorous medical cleaning protocols, and is non-toxic and non-corrosive.

2MicroDome®
CategoryAntimicrobial Polymer Additive
Description

Next-generation antimicrobial additive engineered for seamless integration into various polymer matrices (PLA, nylon, polypropylene, and other thermoplastics, including additive manufacturing/3D printing feedstocks), enabling manufacturers to produce antimicrobial-enhanced products without changing existing processes. Compliant with PMRA's Treated Articles criteria.

3PRP-2019
CategoryAntibiotic Adjuvant Therapeutics
Description

Adjuvant antibiotic technology platform that optimizes inactive commercial antibiotics for infectious diseases by boosting effectiveness against drug-resistant bacteria. Works synergistically with multiple antibiotic classes (demonstrated with Erythromycin against multi-drug-resistant E. coli in Galleria mellonella infection models) without directly killing bacteria, minimizing selection pressure and resistance development.

4Antimicrobial Fabrics
CategoryAntimicrobial Textile Materials
Description

Fabrics integrated with Polyamyna's antimicrobial technologies for use in healthcare facilities, public spaces, and consumer products; inhibit growth of clinically relevant drug-resistant pathogens while maintaining durability and wash resistance.

5Antifouling Technologies
CategoryMarine Antifouling Coatings
Description

Advanced chemistry coatings that prevent accumulation of biofouling organisms on underwater surfaces such as ship hulls and marine infrastructure to enhance operational efficiency and reduce maintenance costs.

6Anti-MIC Technologies
CategoryDefense and Aerospace Antimicrobial Coatings
Description

Antimicrobial coatings tailored for defense and aerospace applications, protecting critical surfaces from microbial contamination and microbially induced corrosion (MIC) in extreme environments.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Newfoundland & Labrador Health Services (NLHS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Clinical trial partner for evaluating Keep Klear's effectiveness against multidrug-resistant pathogens in patient-facing post-surgical medicine wards. Part of a 2023 non-dilutive government-funded initiative to demonstrate product efficacy in real healthcare settings.

polyamyna.ca
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with W21C in Calgary focused on human factors trial to refine the Keep Klear commercialization offering through evaluation of the product's innovation journey.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for research collaboration in antimicrobial technologies and antibiotic discovery. Dr. Kishan Gorityala served as Research Associate and Dr. George Zhanel serves as Professor and Associate Head in Department of Medical Microbiology and Infectious Diseases.

4Canadian Antimicrobial Resistance Alliance (CARA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Advisory partnership with CARA, led by Dr. George Zhanel as Research Director. CARA is dedicated to combatting antimicrobial resistance and provides expert guidance on Polyamyna's research and development direction.

polyamyna.ca
Strategic tierMinorTypeOthers
Description

Engaged with US-EPA regarding regulatory process for claiming residual activity. Successfully passed maximum residual claim requirements for supplemental coatings.

Strategic tierMinorTypeOthers
Description

Health Canada Pest Management Regulatory Agency (PMRA) accepted residual claims for supplemental coatings. Keep Klear PMRA application filed in 2021 with approval target Q4 2025.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global paints and coatings company with antimicrobial coating product lines for healthcare, marine, and industrial markets. Competes with Keep Klear in healthcare coatings, with marine antifouling in the marine vertical, and has the scale to out-resource Polyamyna in enterprise sales.

TypeBroad incumbent
Description

US specialty chemicals company with a broad portfolio of industrial biocides, antimicrobial additives, and preservatives. Competes with MicroDome in polymer/additive markets and with Keep Klear in surface antimicrobial applications at the industrial chemistry level.

TypeBroad incumbent
Description

Swiss global leader in microbial control solutions, biocide active ingredients, and contract manufacturing for pharma and biotech. Competes with MicroDome at the additive/formulation level and overlaps with PRP-2019 on the antimicrobial-therapeutics side.

TypeDirect peer
Description

UK-based medical device coatings company specializing in antimicrobial, antithrombogenic, and biocompatible coatings. Direct peer to Polyamyna in antimicrobial coatings for medical devices and healthcare surfaces.

TypeBroad incumbent
Description

Largest pure-play antimicrobial additives company globally, with technology integrated into thousands of consumer and industrial products. Competes head-to-head with MicroDome in polymer additives and also has surface-coating product lines overlapping with Keep Klear.

TypeDirect peer
Description

Canadian (Mississauga, Ontario) medical device coatings company developing antimicrobial silver-based technologies for catheters, wound dressings, and surface applications. Comparable to Polyamyna in size, geography, antimicrobial-coating focus, and healthcare customer orientation.

TypeDirect peer
Description

UK-based antimicrobial additive technology company that integrates silver-ion and similar additives into polymers, plastics, coatings, and textiles for healthcare and consumer products. Direct overlap with Polyamyna's MicroDome offering and a comparable OEM licensing business model.

TypeDirect peer
Description

US-based antimicrobial additive company (Agion silver-ion, Sciessent odor-control technologies) supplying polymer, textile, and coating manufacturers. Closest US-based direct peer to MicroDome with established FDA/EPA regulatory dossiers and OEM relationships.

9Steri-7 (Bio Technics)
TypeDirect peer
Description

UK-based developer of residual antimicrobial surface disinfectants and coatings for healthcare, food processing, and consumer applications. Closest direct competitor in the residual-effect coating category overlapping with Keep Klear's value proposition.

TypeEmerging player
Description

Clinical-stage antibiotic developer (acquired by Innoviva in 2022) focused on serious drug-resistant infections, including ESKAPE pathogens. Most directly comparable peer for Polyamyna's PRP-2019 adjuvant antibiotic program, with a more advanced clinical stage and larger backing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polyamyna

Antimicrobial Coatings & Infection Prevention Technologiespolyamyna.ca

Polyamyna Nanotech is a Canadian biotechnology company developing nanotechnology-based antimicrobial coatings (Keep Klear™), polymer-integrated antimicrobial additives (MicroDome®), and antibiotic adjuvant therapeutics (PRP-2019) to combat drug-resistant pathogens and healthcare-associated infections for hospitals, OEMs, defense, and marine markets.

What Polyamyna does

Polyamyna Nanotech Inc. is a Canadian biotechnology company (founded 2017–2019, headquartered in St. John's, Newfoundland and Labrador) that develops nanotechnology-based antimicrobial solutions targeting drug-resistant pathogens and healthcare-associated infections (HAIs). It operates a portfolio of three core technologies: Keep Klear™, a continuously active transparent microbicidal coating with a 7-day residual antimicrobial effect and a proprietary electrostatic molecular-arm mechanism; MicroDome®, a registered-trademark antimicrobial additive engineered for integration into polymer matrices (PLA, nylon, polypropylene, thermoplastics, and 3D printing); and PRP-2019, an adjuvant antibiotic platform designed to restore efficacy of existing antibiotics against multi-drug-resistant bacteria without directly killing them. Supporting modules in earlier stages include antimicrobial fabrics, antifouling marine coatings, anti-MIC coatings for defense/aerospace, and a point-of-care diagnostic device for AMR pathogens. An R&D subsidiary was established in Chennai, India in 2021 at Ticel Biopark II.

The company's revenue model is structured around product sales of Keep Klear coatings to healthcare facilities, plus licensing/royalty arrangements for MicroDome (sold or licensed to polymer manufacturers) and potentially PRP-2019 (to pharmaceutical partners). Target verticals span hospitals and long-term care facilities, medical device manufacturers, polymer/OEM manufacturers, defense and aerospace, and marine/offshore infrastructure. GTM combines direct enterprise field sales into healthcare accounts with OEM/embedded integration partnerships for its polymer additive.

Polyamyna remains primarily pre-commercial. Its main activity to date is clinical validation: integration trials with Newfoundland & Labrador Health Services (NLHS) and a human factors study with W21C in Calgary, alongside the Health Canada PMRA approval process for Keep Klear targeted for Q4 2025. Total disclosed funding is approximately $2.26M USD-equivalent across a Genesis pre-seed, 2019 government grants (NL Government, NRC IRAP), 2020 SDTC funding, a 2023 NL Department of Industry non-dilutive grant, and a 2023 SEC Form D debt-to-equity conversion. No institutional VC/PE participation is disclosed.

Polyamyna firmographics

Firmographics
Name
Polyamyna
Legal name
Polyamyna Nanotech Inc.
Website
https://polyamyna.ca
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Polyamyna Nanotech is a Canadian biotechnology company developing nanotechnology-based antimicrobial coatings (Keep Klear™), polymer-integrated antimicrobial additives (MicroDome®), and antibiotic adjuvant therapeutics (PRP-2019) to combat drug-resistant pathogens and healthcare-associated infections for hospitals, OEMs, defense, and marine markets.
Ownership category
akta.pro rank

Polyamyna industry classification

Industry
Product category
Antimicrobial Coatings & Infection Prevention Technologies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252)
SIC
Biological Products, (No Disgnostic Substances) (2836), Miscellaneous Chemical Products (2890), Miscellaneous Plastics Products (3080)
akta.pro industry
PRIMARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Antimicrobial coatings
  • Antimicrobial additives
  • Antibiotic adjuvants
  • Infection prevention
  • Drug resistance therapeutics

Where Polyamyna is headquartered

Location

Headquarters

HQ city
St. John's
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Polyamyna business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Keep Klear Microbicidal Coatings: Sale of continuously active antimicrobial coating products for healthcare facility surfaces. Revenue derived from product sales to hospitals and healthcare systems with demonstrated residual activity lasting up to 7 days per application.
  2. MicroDome Antimicrobial Additive: Licensing and sale of antimicrobial additive technology to polymer manufacturers for integration into their products. Targets healthcare, aerospace, defense, and consumer goods manufacturers.
  3. PRP-2019 Adjuvant Therapeutics: Antibiotic adjuvant compounds for co-administration with existing antibiotics to combat drug-resistant bacteria. Potential licensing to pharmaceutical companies or development as standalone therapeutic products.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Polyamyna product offering

Product offering

Core offering

Polyamyna develops and sells nanotechnology-based antimicrobial products that combat multi-drug-resistant pathogens and healthcare-associated infections. Its core offerings include Keep Klear™, a continuously active transparent microbicidal coating with a 7-day residual effect for healthcare facility surfaces; MicroDome®, an antimicrobial additive for integration into polymer matrices used in manufacturing; and PRP-2019, an antibiotic adjuvant platform that restores efficacy of existing antibiotics against drug-resistant bacteria. Customers include hospitals, healthcare systems, polymer manufacturers, and defense/aerospace integrators.

Product overview

Polyamyna Nanotech Inc. is a biotechnology company offering a portfolio of antimicrobial technologies. The core offerings include Keep Klear™ (a continuously active microbicidal coating with 7-day residual effect), MicroDome® (an antimicrobial additive for polymer integration), and PRP-2019 (an adjuvant antibiotic technology platform). Additional modules include antimicrobial fabrics, antifouling technologies for marine applications, Anti-MIC technologies for defense and aerospace, and a point-of-care diagnostic device for AMR pathogens (in development). These products work together to address infection prevention across healthcare, industrial, and defense settings.

Differentiator

Problem solved

Functional benefit

Brands

  • Keep Klear™: Continuously active transparent microbicidal coating technology offering a 7-day residual effect for infection control in healthcare settings.
  • MicroDome®
  • PRP-2019

Products and services

  • Keep Klear™ Continuously active transparent microbicidal coating technology offering a 7-day residual antimicrobial effect for healthcare surfaces. It eliminates up to 99.99% of infection-causing bacteria, viruses, fungi, and Human Coronavirus, and over 97% of spores and 99.9% of biofilms on coated surfaces; dries in under 10 minutes, withstands rigorous medical cleaning protocols, and is non-toxic and non-corrosive.
  • MicroDome® Next-generation antimicrobial additive engineered for seamless integration into various polymer matrices (PLA, nylon, polypropylene, and other thermoplastics, including additive manufacturing/3D printing feedstocks), enabling manufacturers to produce antimicrobial-enhanced products without changing existing processes. Compliant with PMRA's Treated Articles criteria.
  • PRP-2019 Adjuvant antibiotic technology platform that optimizes inactive commercial antibiotics for infectious diseases by boosting effectiveness against drug-resistant bacteria. Works synergistically with multiple antibiotic classes (demonstrated with Erythromycin against multi-drug-resistant E. coli in Galleria mellonella infection models) without directly killing bacteria, minimizing selection pressure and resistance development.
  • Antimicrobial Fabrics Fabrics integrated with Polyamyna's antimicrobial technologies for use in healthcare facilities, public spaces, and consumer products; inhibit growth of clinically relevant drug-resistant pathogens while maintaining durability and wash resistance.
  • Antifouling Technologies Advanced chemistry coatings that prevent accumulation of biofouling organisms on underwater surfaces such as ship hulls and marine infrastructure to enhance operational efficiency and reduce maintenance costs.
  • Anti-MIC Technologies Antimicrobial coatings tailored for defense and aerospace applications, protecting critical surfaces from microbial contamination and microbially induced corrosion (MIC) in extreme environments.

Quantifiable outcome

  • Eliminates >99% of MRSA within 15 minutes of contact on coated surfaces
  • +6 more outcomes

Companies that use Polyamyna

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Polyamyna technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Polyamyna partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Newfoundland & Labrador Health Services (NLHS)coreStrategic or Co-development Partner · 1 January 2023Clinical trial partner for evaluating Keep Klear's effectiveness against multidrug-resistant pathogens in patient-facing post-surgical medicine wards. Part of a 2023 non-dilutive government-funded initiative to demonstrate product efficacy in real healthcare settings.
  • W21C Research InstitutecoreStrategic or Co-development PartnerPartnership with W21C in Calgary focused on human factors trial to refine the Keep Klear commercialization offering through evaluation of the product's innovation journey.
  • University of ManitobacoreStrategic or Co-development PartnerAcademic partnership for research collaboration in antimicrobial technologies and antibiotic discovery. Dr. Kishan Gorityala served as Research Associate and Dr. George Zhanel serves as Professor and Associate Head in Department of Medical Microbiology and Infectious Diseases.
  • Canadian Antimicrobial Resistance Alliance (CARA)coreStrategic or Co-development PartnerAdvisory partnership with CARA, led by Dr. George Zhanel as Research Director. CARA is dedicated to combatting antimicrobial resistance and provides expert guidance on Polyamyna's research and development direction.
  • US Environmental Protection Agency (US-EPA)minorOthersEngaged with US-EPA regarding regulatory process for claiming residual activity. Successfully passed maximum residual claim requirements for supplemental coatings.
  • Health CanadaminorOthersHealth Canada Pest Management Regulatory Agency (PMRA) accepted residual claims for supplemental coatings. Keep Klear PMRA application filed in 2021 with approval target Q4 2025.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Polyamyna competitors and assessment

Company assessment

Broad incumbents

  • AkzoNobel: Global paints and coatings company with antimicrobial coating product lines for healthcare, marine, and industrial markets. Competes with Keep Klear in healthcare coatings, with marine antifouling in the marine vertical, and has the scale to out-resource Polyamyna in enterprise sales.
  • Troy Corporation: US specialty chemicals company with a broad portfolio of industrial biocides, antimicrobial additives, and preservatives. Competes with MicroDome in polymer/additive markets and with Keep Klear in surface antimicrobial applications at the industrial chemistry level.
  • Lonza Group: Swiss global leader in microbial control solutions, biocide active ingredients, and contract manufacturing for pharma and biotech. Competes with MicroDome at the additive/formulation level and overlaps with PRP-2019 on the antimicrobial-therapeutics side.
  • Microban International: Largest pure-play antimicrobial additives company globally, with technology integrated into thousands of consumer and industrial products. Competes head-to-head with MicroDome in polymer additives and also has surface-coating product lines overlapping with Keep Klear.

Direct peers

  • Biointeractions: UK-based medical device coatings company specializing in antimicrobial, antithrombogenic, and biocompatible coatings. Direct peer to Polyamyna in antimicrobial coatings for medical devices and healthcare surfaces.
  • Covalon Technologies: Canadian (Mississauga, Ontario) medical device coatings company developing antimicrobial silver-based technologies for catheters, wound dressings, and surface applications. Comparable to Polyamyna in size, geography, antimicrobial-coating focus, and healthcare customer orientation.
  • BioCote: UK-based antimicrobial additive technology company that integrates silver-ion and similar additives into polymers, plastics, coatings, and textiles for healthcare and consumer products. Direct overlap with Polyamyna's MicroDome offering and a comparable OEM licensing business model.
  • Sciessent (formerly Agion Technologies): US-based antimicrobial additive company (Agion silver-ion, Sciessent odor-control technologies) supplying polymer, textile, and coating manufacturers. Closest US-based direct peer to MicroDome with established FDA/EPA regulatory dossiers and OEM relationships.
  • Steri-7 (Bio Technics): UK-based developer of residual antimicrobial surface disinfectants and coatings for healthcare, food processing, and consumer applications. Closest direct competitor in the residual-effect coating category overlapping with Keep Klear's value proposition.

Emerging players

  • Entasis Therapeutics (an Innoviva company): Clinical-stage antibiotic developer (acquired by Innoviva in 2022) focused on serious drug-resistant infections, including ESKAPE pathogens. Most directly comparable peer for Polyamyna's PRP-2019 adjuvant antibiotic program, with a more advanced clinical stage and larger backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Polyamyna social profiles

Digital presence

Polyamyna compliance and trust

Trust signal

Compliance2 records

Polyamyna financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polyamyna leadership team

Management profile

Number of profiles

Profiles8 records

Polyamyna subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Polyamyna funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polyamyna M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polyamyna

What does Polyamyna do?

Polyamyna develops and sells nanotechnology-based antimicrobial products that combat multi-drug-resistant pathogens and healthcare-associated infections. Its core offerings include Keep Klear™, a continuously active transparent microbicidal coating with a 7-day residual effect for healthcare facility surfaces; MicroDome®, an antimicrobial additive for integration into polymer matrices used in manufacturing; and PRP-2019, an antibiotic adjuvant platform that restores efficacy of existing antibiotics against drug-resistant bacteria. Customers include hospitals, healthcare systems, polymer manufacturers, and defense/aerospace integrators.

Is Polyamyna a public or private company?

Polyamyna is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Polyamyna founded?

Polyamyna was founded in 2019. It employs 11 to 50 people.

Where is Polyamyna based?

Polyamyna is headquartered in St. John's, Canada, in the North America region.

How does Polyamyna make money?

Three revenue lines are on record. Keep Klear Microbicidal Coatings are the primary driver. The others are microDome Antimicrobial Additive and PRP-2019 Adjuvant Therapeutics.

Who are Polyamyna's main competitors?

Broad incumbents on record are AkzoNobel, Troy Corporation, Lonza Group and Microban International. Direct peers are Biointeractions, Covalon Technologies, BioCote, Sciessent (formerly Agion Technologies) and Steri-7 (Bio Technics). Entasis Therapeutics (an Innoviva company) is listed as an emerging player.

Does Polyamyna have an API?

No public API is recorded for Polyamyna.

What industry is Polyamyna in?

Polyamyna's product category is Antimicrobial Coatings & Infection Prevention Technologies. Its primary akta.pro industry code is HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives, with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals